Canary Cure Therapeutics is known for its work in ext-generation RNA therapeutics development and this month, the company introduced its game-changing obesity therapy. The preclinical results of CCT-217 have shown positive results in tackling two challenges for obesity therapy — muscle mass loss and poor medication adherence. Raj Reddy, CEO of Canary Cure, shared about the promising innovation: “CCT-217’s unique dual-mechanism approach represents a fundamental advancement in obesity treatment. While current therapies often result in significant muscle loss – up to 40% of total weight loss – our technology selectively targets fat tissue while protecting and enhancing lean muscle mass, a critical factor for long-term metabolic health.”

CCT-217 works to leverage RNA interference (RNAi) to silence CB1R and ZFP423, which are two of the genes involved in fat storage and metabolism.

Image Credit: Canary Cure Therapeutics